![]() ![]() The results are expected to be released on March 1. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Īnother stock from the same industry, Intra-Cellular Therapies (ITCI), has yet to report results for the quarter ended December 2022. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is -$2.36 on $2.19 million in revenues for the coming quarter and -$8.21 on $193.46 million in revenues for the current fiscal year. ![]() It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for CRISPR Therapeutics AG: mixed. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. ![]() There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While CRISPR Therapeutics AG has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.ĬRISPR Therapeutics AG shares have added about 25.2% since the beginning of the year versus the S&P 500's gain of 6.2%. The company has not been able to beat consensus revenue estimates over the last four quarters. This compares to year-ago revenues of $12.9 million. The lowered outlook extended to the bottom line, and the company is now guiding for adjusted diluted EPS in a range of $0.29 to $0.32, down from its previous range of $0.38 to $0.41.CRISPR Therapeutics AG, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.01 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 99.95%. Citing the macroeconomic challenges that remain, Krispy Kreme is now guiding for full-year revenue in a range of $1.49 billion to $1.52 billion, representing growth of 8.7% at the midpoint of its guidance, down from its previous forecast for 11.6% growth, which management issued just three months ago. Perhaps the most disappointing point for investors was that management lowered its guidance. Additionally, Krispy Kreme signed agreements to enter four new international markets, including Switzerland, Chile, Costa Rica, and Jordan, while increasing its footprint in Turkey. It continued to increase its footprint, however, expanding the number of locations where its fresh doughnuts can be purchased by 382, bringing the total to more than 11,400 worldwide. ![]() In addition to higher input costs, the company cited softer consumer spending and the heatwave in the U.K. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |